Gilead Sciences beat third-quarter sales estimates and issued cautious guidance late Tuesday, as its bottom line was hit by an ObamaCare-related fee. The stock slipped 4% after hours following a new record high during the regular session. Gilead (GILD) revenue rose 117% to $6.04 billion, beating analysts’ consensus by about $50 million. Earnings leapt 254% to $1.84 a share, but 8 cents short of the Street’s estimate. But Gilead said
Twitter reported better-than-expected Q3 revenue late Monday, but the social site’s slower user growth and engagement, along with weaker sales guidance, sent shares sharply lower. Average monthly users hit 284 million at the end of Q3, up 23% vs. a year earlier. But the 13 million new users translates to a 5% sequential gain vs. Q2’s 6.2% rise. Sterne Agee analyst Arvind Bhatia said in a Sunday report that he expected 285
Apple trounced Wall Street forecasts late Monday due to red-hot sales of its iPhone 6 smartphones and Mac computers. The tech titan also guided sales estimates higher for the holiday quarter. For its fiscal fourth quarter ended Sept. 27, Apple (AAPL) earned $1.42 a share, up 20% from a year earlier and topping analysts’ consensus forecast by 11 cents. Sales rose 12% to $42.1 billion, easily beating the target of $39.88 billion. It